Want to see HK:9877 full AI Analyst Report?
9877 Stock Chart & Stats
HK$9.48
HK$0.16(3.97%)
At close: 4:00 PM EST
HK$9.48
HK$0.16(3.97%)
Day’s Range― - ―
52-Week RangeHK$6.70 - HK$11.98
Previous CloseN/A
Volume216.80K
Average Volume (3M)805.10K
Market Cap
HK$4.18B
Enterprise ValueHK$2.12B
Total Cash (Recent Filing)HK$527.63M
Total Debt (Recent Filing)HK$47.38M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding310,306,200
10 Day Avg. Volume637,060
30 Day Avg. Volume805,099
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)4.22
Price to Sales (P/S)37.79
P/FCF Ratio-41.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.09
Revenue Forecast (FY)HK$261.02M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Unit EconomicsA sharp revenue ramp to ~88.2M in 2025 combined with ~75% gross margin shows the company is converting commercialization into high-margin sales. These unit economics support scalable revenue growth and margin retention as procedural adoption of transcatheter solutions increases.
Low Financial LeverageVery low leverage (debt-to-equity ~0.06) means solvency risk is limited, giving management flexibility to fund commercialization through equity or modest debt without immediate distress. This balance-sheet resilience matters while the business transitions toward sustained positive cash flow.
Focused Structural Heart FranchiseJenscare’s focused franchise in structural heart disease and transcatheter solutions targets a durable, growing market with high clinical barriers and adoption cycles. A specialized product focus supports competitive differentiation and long-term recurring procedure-driven demand.
Bears Say
Large And Persistent LossesA net loss of ~264.2M in 2025 demonstrates the company remains far from profitability. Sustained material losses can erode equity, force dilutive capital raises, and limit strategic optionality, making the path to positive earnings a multi-period, execution‑sensitive task.
Negative Cash Flow & Funding NeedsOperating cash flow and free cash flow remain negative (~-75M and ~-80M), indicating ongoing cash burn despite improvement. Continued funding requirements raise execution risk, increase probability of dilution or constrained investment, and limit ability to scale commercial efforts steadily.
Profitability Conversion / High OpExOperating expenses remain well ahead of current revenue and ROE is roughly -33%, signaling poor conversion of sales into shareholder returns. High fixed and operating spend lengthen the runway to break-even and make profitability highly sensitive to the pace of revenue growth and adoption.
Jenscare Scientific Co. Ltd. Class H News
9877 FAQ
What was Jenscare Scientific Co. Ltd. Class H’s price range in the past 12 months?
Jenscare Scientific Co. Ltd. Class H lowest stock price was HK$6.70 and its highest was HK$11.98 in the past 12 months.
What is Jenscare Scientific Co. Ltd. Class H’s market cap?
Jenscare Scientific Co. Ltd. Class H’s market cap is HK$4.18B.
When is Jenscare Scientific Co. Ltd. Class H’s upcoming earnings report date?
Jenscare Scientific Co. Ltd. Class H’s upcoming earnings report date is Sep 02, 2026 which is in 56 days.
How were Jenscare Scientific Co. Ltd. Class H’s earnings last quarter?
Jenscare Scientific Co. Ltd. Class H released its earnings results on Mar 26, 2026. The company reported -HK$0.29 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.29.
Is Jenscare Scientific Co. Ltd. Class H overvalued?
According to Wall Street analysts Jenscare Scientific Co. Ltd. Class H’s price is currently Overvalued.
Does Jenscare Scientific Co. Ltd. Class H pay dividends?
Jenscare Scientific Co. Ltd. Class H does not currently pay dividends.
What is Jenscare Scientific Co. Ltd. Class H’s EPS estimate?
Jenscare Scientific Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jenscare Scientific Co. Ltd. Class H have?
Jenscare Scientific Co. Ltd. Class H has 310,306,200 shares outstanding.
What happened to Jenscare Scientific Co. Ltd. Class H’s price movement after its last earnings report?
Jenscare Scientific Co. Ltd. Class H reported an EPS of -HK$0.29 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.222%.
Which hedge fund is a major shareholder of Jenscare Scientific Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:9877
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jenscare Scientific Co. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
201.35%
12-Months-Change
Fundamentals
Return on Equity
-22.25%
Trailing 12-Months
Asset Growth
-8.72%
Trailing 12-Months
Company Description
Jenscare Scientific Co. Ltd. Class H
Jenscare Scientific Co., Ltd. operates as a medical technology enterprise dedicated to advancing interventional therapies for structural heart conditions within the People's Republic of China. Among its pipeline, the company features LuX-Valve, an investigational transcatheter tricuspid valve replacement (TTVR) system designed for patients suffering from severe tricuspid regurgitation who face elevated surgical risks. Additionally, Ken-Valve represents another key product candidate, a transcatheter aortic valve replacement (TAVR) aimed at addressing severe aortic regurgitation, often co-occurring with aortic stenosis. The applications of Jenscare's portfolio extend to a range of structural cardiac maladies, including disorders of the tricuspid, aortic, and mitral valves, as well as heart failure. Founded in 2011, the company maintains its principal place of business in Ningbo, People's Republic of China.
Technical Analysis
Peijia Medical Ltd.
―
LifeTech Scientific Corporation
―
Shanghai Kindly Medical Instruments Co., Ltd. Class H
―
AK Medical Holdings Ltd.
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---